Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 764-769

  Susen, S ^a   Hazzan, M ^a   Labalette, M ^a   Zawadzki, C ^a   Dessaint, J P ^a   Lelievre, G ^a   Jude, B ^a   Noel, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Endothelium; Pentoxyfilline; Renal transplantation; Tissue factor

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MEPREDNISONE; OKT 3; PENTOXIFYLLINE; STEROID; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CELL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN CELL; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 0033708927     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614112     Document Type: Article

References (52)

1. Tissue factor and hemostasis
2. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody
3. Tissue factor as a tumor procoagulant
4. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina
5. The structural biology of expression and function of tissue factor
6. Allogeneic induction of the human T cell-instructed monocyte procoagulant response is rapid and is elicited by HLA-DR
7. Increased tissue factor activity of monocytes/macrophages isolated from canine renal allografts
8. Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system
9. Monocyte procoagulant activity and plasminogen activator. Role in human allograft rejection
10. Increased tissue factor activity generation in vitro by canine blood leukocytes associated with allogeneic kidney transplantation and rejection
11. The significance of elevated procoagulant activity in the monocytes of renal allograft
12. Hemostasis and fibrinolysis in renal transplantation
13. Primary haemostasis, plasmatic coagulation and fibrinolysis in renal transplantation
14. Natural anticoagulant and fibrinolytic pathways in renal allograft failure
15. Monocyte modulation of endothelial leukocyte adhesion molecules
16. Pentoxifylline: A potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells
17. Effects of pentoxifylline on the modulation by cytokines of thrombomodulin and tissue factor activities on the surface of human endothelial cells in culture
18. Improvement in the outcome of rejection with pentoxifylline in renal transplantation
19. Tissue factor activity in HeLa cells measured with a continuous chromogenic assay and ELISA reader
20. Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells
21. Tissue factor induction in human monocytes. Two distinct mechanisms displayed by different alloantigen-responsive T cell clones
22. Cytokine-induced procoagulant activity in monocytes and endothelial cells
23. Induction of monocyte procoagulant activity with OKT3 antibody
24. Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody
25. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes
26. Interleukin-10 and pentoxifylline inhibit C reactive protein-induced tissue factor gene expression in peripheral human monocytes
27. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelal growth factor
28. Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells
29. Nephrotoxicity of cyclosporine A after allogenic marrow transplantation: Glomerular thrombosis and tubular injury
30. Glomerular thrombi in renal allografts associated with cyclosporine treatment
31. Thromboembolic complications in cyclosporine treated kidney allograft recipients
32. Allogenic induction of thromboplastin synthesis in monocytes and endothelial cells. Biphasic effect of cyclosporin A
33. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients
34. A randomized controlled trial of pentoxifylline for the prevention of the delayed graft function in cadaveric kidney graft
35. von Willebrand Factor a marker of endothelial damage?
36. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
37. Prospective study of endogenous tissue plasminogen activator and risk of stroke
38. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
39. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: Evidence for a dynamic storage pool
40. von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Sequential measurements over 4 months in 17 patients
41. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure
42. Changes in coagulation and fibrinolysis in the postoperative period immediately after kidney transplantation in patients receiving OKT3 or cyclosporine A as induction therapy
43. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients
44. Plasma thrombomodulin levels are dependent on renal function
45. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy
46. Thrombomodulin: A marker for endothelial damage during orthotopic liver transplantation
47. Circulating thrombomodulin as a molecular marker of endothelium damage in renal transplant recipients
48. Purine nucleotides induce regulated secretion of von Willebrand factor: Involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis
49. Adenosine 3':5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells
50. Cyclic AMP increases thrombomodulin expression on membrane surface of cultured human umbilical vein endothelial cells
51. Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions
52. Pentoxifylline prevents tumor necrosis factor-induced suppression of endothelial cell surface thrombomodulin